Bavituximab
Bavituximab is a monoclonal antibody that has been investigated for its potential use in the treatment of various types of cancer and viral infections. It is a chimeric monoclonal antibody that targets phosphatidylserine, a molecule that becomes exposed on the surface of cells in the tumor vasculature and virally infected cells.
Mechanism of Action[edit]
Bavituximab binds to phosphatidylserine, which is normally located on the inner leaflet of the cell membrane but becomes externalized in certain pathological conditions. By targeting phosphatidylserine, bavituximab is thought to help the immune system recognize and destroy tumor cells and virally infected cells. This mechanism involves the recruitment of immune cells such as macrophages and natural killer cells to the site of the tumor or infection.
Clinical Development[edit]
Bavituximab has been evaluated in several clinical trials for its efficacy and safety in treating various cancers, including non-small cell lung cancer, breast cancer, and hepatocellular carcinoma. It has also been studied for its potential use in treating viral infections such as hepatitis C.
Cancer[edit]
In cancer treatment, bavituximab has been tested in combination with other therapies such as chemotherapy and radiation therapy. Clinical trials have shown mixed results, with some studies indicating potential benefits in terms of tumor reduction and patient survival, while others have not demonstrated significant improvements.
Viral Infections[edit]
For viral infections, bavituximab has been explored as a treatment for chronic hepatitis C. Early-phase clinical trials have shown some promise, but further research is needed to establish its efficacy and safety in this context.
Side Effects[edit]
The side effects of bavituximab are similar to those of other monoclonal antibodies and can include infusion reactions, fatigue, nausea, and fever. More serious side effects may include immune-related adverse events and cytokine release syndrome.
Current Status[edit]
As of the latest updates, bavituximab is not yet approved for general clinical use and remains an investigational drug. Ongoing research continues to explore its potential applications and to better understand its mechanism of action and therapeutic benefits.
See Also[edit]
References[edit]
External Links[edit]
-
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
